Daunorubicin metabolism in acute nonlymphocytic leukemia
Daunorubicin metabolism in acute nonlymphocytic leukemia
复制标题
急性非淋巴细胞白血病中柔红霉素的代谢
DOI：
10.1002/cpt1972136895
复制
发表时间：
1972
影响因子：
6.7
通讯作者：
N. Bachur
中科院分区：
文献类型：
--
作者：
D. Huffman;R. Benjamin;N. Bachur
柔红霉素及其主要人体代谢物柔红霉素醇和两种先前未发现的代谢物的药代动力学评价，为急性非淋巴细胞白血病患者体内柔红霉素的代谢提供了信息。柔红霉素是血浆和尿液中的主要荧光物质，是组织中的重要代谢物。在8例患者中，柔红霉素和柔红霉素的平均血浆半衰期分别为18.5±4.86 h S.D.和26.7±12.8 h S.D.。在其中4例患者中，柔红霉素和柔红霉素的血浆半衰期相等，表明不同个体的药代动力学存在差异。这些观察结果，连同早期证实的白血病患者白血病白细胞在体外产生的柔红霉素增加，表明柔红霉素在柔红霉素治疗的药效学中起着重要作用。其中一种新的代谢物D5是人类心脏的主要荧光物质。
The pharmacokinetic evaluation of daunorubicin and its principal human metabolites, daunorubicinol and two previously unidentified metabolites, has provided information concerning the in vivo metabolism of daunorubicin in patients with acute non lymphocytic leukemia. Daunorubicinol was the maior fluorescent material present in plasma and urine and was a significant metabolite in the tissues. For 8 patients, the mean plasma half‐lifes of daunorubicin and daunorubicinol were 18.5 ± 4.86 hours S.D. and 26.7 ± 12.8 hours S.D., respectively. In 4 of these patients the plasma half‐lifes of daunorubicin and daunorubicinol were equal, indicating a variability of the pharmacokinetics in different individuals. These observations together with the earlier demonstration of increased production of daunorubicinol in vitro by leukemic leukocytes from responding patients indicate a significant role for daunorubicinol in the pharmacodynamics of daunorubicin therapy. One of the new metabolites, D5, was the predominant fluorescent material in human heart.